Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 08

2287P - Multiomic Biological mOdifications in the immune response of patients treated with chemotherapy, anti-CD20, or immune-checkpoint inhibitors and receiving a Third dose of vaccinE against SARS-CoV-2 (the BO0STER study)

Date

21 Oct 2023

Session

Poster session 08

Topics

Tumour Immunology;  Translational Research;  COVID-19 and Cancer

Tumour Site

Presenters

Gabriele Zoppoli

Citation

Annals of Oncology (2023) 34 (suppl_2): S1152-S1189. 10.1016/S0923-7534(23)01927-0

Authors

G. Zoppoli1, L. Ferrando2, F. Ravera3, M. Dameri4, I. Lombardo2, M. Stabile3, N. Fallani3, B. Cigolini3, G. Gentilcore5, B. Bruzzone6, A. Domnich6, A. Orsi7, F. Ballerini8, D. Rinchai9, D. Chaussabel10, D. Bedognetti3, J. Grivel11, C. Genova12, R. Lemoli13, A. Ballestrero1

Author affiliations

  • 1 Dimi - Dipartimento Di Medicina Interna E Specialità Mediche, DiMI Università degli Studi di Genova e Ospedale Policlinico San Martino IRCCS, 16132 - Genova/IT
  • 2 Dimi - Dipartimento Di Medicina Interna E Specialità Mediche, IRCCS Ospedale Policlinico San Martino, 16132 - Genova/IT
  • 3 Dimi - Dipartimento Di Medicina Interna E Specialità Mediche, DiMI Università degli Studi di Genova, 16132 - Genova/IT
  • 4 Dimi - Dipartimento Di Medicina Interna E Specialità Mediche, DiMI Università degli Studi di Genova, 16132 - Genoa/IT
  • 5 Advanced Cell Therapy Core, Sidra Medicine, Doha, QR, Doha/QA
  • 6 Unità Operativa Igiene, IRCCS Ospedale Policlinico San Martino, 16132 - Genova/IT
  • 7 Dissal Dipartimento Di Scienze Della Salute, DISSAL Università degli Studi di Genova, 16132 - Genova/IT
  • 8 Clinica Ematologica, IRCCS Ospedale Policlinico San Martino, 16132 - Genova/IT
  • 9 Laboratory Of Human Genetics Of Infectious Diseases, The Rockefeller University, New York/US
  • 10 Computational Sciences Department, The Jackson Laboratory for Genomic Medicine, 06032 - Farmington/US
  • 11 Program On Physical Biology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD/US
  • 12 Lung Cancer Unit, DiMI Università degli Studi di Genova e Ospedale Policlinico San Martino IRCCS, 16132 - Genova/IT
  • 13 Dimi - Dipartimento Di Medicina Interna E Specialità Mediche, Università degli Studi di Genova e Ospedale Policlinico San Martino IRCCS - DiMI, 16132 - Genova/IT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 2287P

Background

Antibody titers after two doses of mRNA-based SARS-Cov-2 vaccines (SVC) decline after 6 months, requiring a further dose to boost immune response. Anticancer agents may differentially impact the response to SVC, but a direct comparison between patients and with healthy controls (HC) has not been conducted. We serially assessed the immunomic changes associated with the booster dose of SVC in patients treated with adjuvant chemotherapy (aCT, colorectal and breast cancer), rituximab (R, non-Hodgkin lymphoma), immune checkpoint inhibitors (ICI, solid tumors), and HC.

Methods

In the above mentioned groups, we performed blood transcriptome sequencing (TS), multiplex antibody titer (ABt, Spherotech), and SARS-CoV-2-specific IFN release assay (IGRA) before the third vaccine dose (TS/AT/IGRA), after 24 hours (TS), at 5 days (d - TS/IGRA), 26d (AT/IGRA) and after six months (mo - AT/IGRA). Immune transcriptomic modules were assessed using BloodGene3.

Results

We enrolled 52 subjects: 11 R, 11 ICI, 8 aCT, and 22 HC. aCT or ICI showed similar vaccine-specific ABt compared with HC at 26d, increasing at 6mo. ICI showed a significantly reduced increase of IgG2 vaccine-specific ABt at 26d compared with HC. R showed a blunted response at 26d. In all groups, the Env and Core ABt increased significantly at 6mo (81% of subjects), with symptomatic infection in only 31% of subjects. We observed a delayed (5d) but efficient increase in inflammation and chemochine modules in aCT, reduced early inflammation (24h) and increased delayed plasma-cell response (5d) in ICI, and reduced response to all immune modules, except for a delayed increase in IFN modules (5d), in R compared with HC. IGRA results were consistent with IFN modules, with a 5d increase in R.

Conclusions

Patients undergoing aCT and ICI mount a vaccine-mediated immunomic response in part similar, but not identical, to HC, and R patients show a blunted vaccine response in line with the literature. A large fraction of all enrolled subjects developed ABt against natural infection, in the absence of symptoms, at 6mo.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

IRCCS Policlinico San Martino, Genoa IT.

Funding

University of Genoa , 5x1000 IRCCS funds, AIRC, ACC.

Disclosure

G. Zoppoli: Financial Interests, Personal, Stocks or ownership: Immunomica Srl; Financial Interests, Personal, Invited Speaker: Novartis; Non-Financial Interests, Institutional, Product Samples: ThermoFisher Scientific; Non-Financial Interests, Personal, Other, Travel grant: Novartis, Roche. C. Genova: Financial Interests, Personal, Invited Speaker, Speaker's Bureau (scientific meeting): AstraZeneca, Bristol Myers Squibb, Merck Sharp & Dohme, Eli Lilly, Novartis; Financial Interests, Personal, Advisory Board, Advisory board: Amgen, Sanofi; Financial Interests, Personal, Advisory Board, Advisory Board: Roche, Takeda; Financial Interests, Institutional, Funding, Funding for support of translational study: Bristol Myers Squibb; Financial Interests, Institutional, Funding, Funding in support of translational study: AstraZeneca; Financial Interests, Institutional, Research Grant, Research Grant for translational study: Italian Ministry of Health; Non-Financial Interests, Principal Investigator, Local PI for clinical trials: AstraZeneca, Roche; Non-Financial Interests, Member, Scientific Society Membership: ASCO, AIOM, FONICAP, AIOT, IASLC, ISLB. R. Lemoli: Financial Interests, Other: Jazz, Pfizer, AbbVie, BMS, Sanofi, StemLine. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.